CD4-CM140-100μg / 询价
CD4-CM140-500μg / 询价
CD4-CM140-500μgx2 / 询价
Cynomolgus CD40/TNFRSF5 Protein
Recombinant Cynomolgus CD40/TNFRSF5 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu21-Arg193 [Accession | G7PG38].
The protein has a predicted MW of 20.3 kDa. Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus CD40 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Cynomolgus CD40 is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus CD40, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Human CD40 Ligand (Trimer) , hFc Tag with the EC50 of 4.1ng/ml determined by ELISA (QC Test).
CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.CD40 molecule is a potential target for cancer immunotherapy. There are number of completed and ongoing clinical trials where agonistic anti-CD40 monoclonal antibodies are employed to activate an anti-tumor T cell response via activation of dendritic cells.
CD40; CD40L receptor; TNFRSF5; CD40 antigen; CD40 molecule; CDw40; MGC9013;
(1)Pound, J. D. Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells[J]. International Immunology, 1999, 11(1):11-20
